Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab. | Available online http content 9 3 R61 Research article A 1-year case-control study in patients with rheumatoid arthritis indicates prevention of loss of bone mineral density in both responders and nonresponders to infliximab Hubert Marotte1 Beatrice Pallot-Prades2 Laurent Grange3 Philippe Gaudin3 Christian Alexandre2 and Pierre Miossec1 Open Access 1Hospices Civils de Lyon-bioMérieux Research Unit on Rheumatoid Arthritis Hopital Edouard Herriot place d Arsonval 69437 Lyon Cedex 03 France 2Department of Rheumatology University Hospital Hopital Bellevue 42000 Saint-Etienne France 3Department of Rheumatology University Hospital Hopital Sud 38000 Grenoble France Corresponding author Pierre Miossec miossec@ Received 23 Jan 2007 Revisions requested 5 Mar 2007 Revisions received 19 Jun 2007 Accepted 27 Jun 2007 Published 27 Jun 2007 Arthritis Research Therapy 2007 9 R61 doi ar2219 This article is online at http content 9 3 R61 2007 Marotte et al. licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract The goal of the present study was to record changes in bone mineral density BMD and markers of bone turnover in patients with rheumatoid arthritis RA who were treated with methotrexate combined or not combined with infliximab. Included were 90 patients with RA who required anti-TNF-a therapy with infliximab because of persistent active disease despite treatment with methotrexate. The historical control group included 99 patients with RA who were treated with methotrexate at a time when anti-TNF-a treatment was not yet available. Lumbar and femoral neck BMD was measured using dual energy X-ray absorptiometry at baseline and 1 year later. Osteocalcin C-terminal .
